Drug Profile

BY 002

Alternative Names: BY-002

Latest Information Update: 11 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beyang Therapeutics
Class Antineoplastics
Mechanism of Action KMT2A protein inhibitors; Menin inhibitors; Nucleophosmin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase I Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma

15 Nov 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (PO) (NCT07270770)
15 Nov 2025 Phase-I clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in China (PO) (NCT07270770)
04 Aug 2025 Early research in Acute myeloid leukaemia in China (PO) before August 2025 (Beyang Therapeutics pipeline, August 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com